Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
Tevogen (Nasdaq: TVGN) outlined recent progress in making allogeneic T cell therapies more accessible, citing dose-finding clinical data for TVGN 489 and demand from Long COVID patients. Management highlighted an rNPV valuation of $9–$11 billion for TVGN 489 and a projected 5-year top-line revenue of ~ $6.5 billion for a liver-cancer prevention product targeting high-risk chronic Hepatitis B. Tevogen.AI completed alpha and began beta of PredicTcell, reported large time reductions in target analysis with potential billions in development savings, and received an international patent publication (WO2025/129197). The company expanded headquarters and created a Long COVID contact channel receiving global inquiries.
- rNPV valuation of $9–$11 billion for TVGN 489
- 5-year revenue estimate of ~ $6.5 billion for HBV-related product
- PredicTcell alpha complete; beta build begun with Microsoft and Databricks
- International patent publication WO2025/129197 for ML peptide prediction
- Company states it will need to raise additional capital to execute plans
- Tevogen has a limited operating history
- Development and approval risks could delay commercialization
Insights
Company highlights clinical dose-finding signals for TVGN 489, AI IP progress, and large internal valuations and revenue projections.
Tevogen emphasizes progress toward scalable, allogeneic T cell therapies by citing dose-finding clinical data for TVGN 489 and multiple intellectual property filings, including a PCT on AI peptide prediction (Publication Number WO2025/129197). The release also publicizes an internal rNPV valuation of
Key dependencies and risks are explicit in the text: clinical development and regulatory outcomes, the need for additional capital, and operational execution. The company also frames AI work as a development-efficiency lever and notes an international patent publication for that AI, but those items are descriptive IP and development milestones rather than clinical end points.
Concrete items to watch include publication or full data sets for the TVGN 489 dose-finding study, any regulatory filings or trial milestones tied to that program, the status of the AI patent family (national-stage progress), and announcements about capital raises or manufacturing scale-up; expect these near-term milestones within clinical and IP timelines over the next 12–24 months.
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company’s significant progress toward making precision medicine accessible to all.
“The full potential of T cell therapies has yet to be explored. To matter, they must be accessible, off-the-shelf, well tolerated with durable persistence, and, most importantly, affordable for the masses through low development costs,” Ryan Saadi, MD, MPH, Founder of Tevogen, shared while speaking to industry leaders. “Our biotech initiative is developing exactly that across cancers, neurologic diseases, and viral infections, and dose-finding clinical data for TVGN 489 align with this profile. With over 20 million Long COVID patients just in the U.S., and families contacting us from around the world about TVGN 489, we’re doing everything possible to expedite.”
“Tevogen is hoping to develop exactly that across cancers and viral infections and our dose-finding clinical data for TVGN 489 aligns with this profile. With over 20 million Long COVID patients just in the U.S., and families contacting us from around the world about TVGN 489, we’re doing everything possible to expedite.”
Recent Financial Announcements
- Values TVGN 489 at
$9 –$11 billion rNPV, its first clinical product from the proprietary ExacTcell™ allogeneic T cell platform. - Estimates 5-Year top-line revenue of ∼
$6.5 billion for product focused on liver cancer prevention with high-risk chronic Hepatitis B infection.
Recent Artificial Intelligence Announcements
- Tevogen.AI completes alpha and begins beta build of proprietary PredicTcell™ model with Microsoft and Databricks.
- Observes drastic time reduction in target analysis translating to potential savings of billions in drug development costs.
- Tevogen.AI receives international patent publication for AI technology predicting immunologically active peptides.
Recent Corporate Announcements
- Headquarters expanded to centralizes R&D and AI teams.
- Long COVID contact channel, longCOVID@tevogen.com, created which has received inquiries from every major continent, underscoring the global demand for durable solutions.
Intellectual Property:
Tevogen Bio received two granted patents in December 2021 and one in January 2022 from the United States Patent and Trademark Office (USPTO) for Covid-19 Peptide Specific T-Cells and Methods of Treating and Preventing Covid-19.
In June 2022, a Patent Cooperation Treaty (PCT) application covering Virus Specific T-Cells and Methods of Treating and Preventing Viral Infections was published. This application entered the National Stage in the US, Australia, Canada, Europe, Hong Kong, and Japan.
- Publication Number WO 2022/125746
In February 2023, a PCT application covering Methods for Developing CD3+CD8+ Cells Against Multiple Viral Epitopes for Treatment of Viral Infections Including Variants Evolving to Escape Previous Immunity was published. This application entered the National Stage in the US, Australia, Canada, Europe, Japan, Qatar, Saudi Arabia, and United Arab Emirates.
- Publication Number WO 2023/009770
In June 2025, a PCT application covering Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models was published.
- Publication Number WO2025/129197
Tevogen Bio also has one provisional patent application in place as of December 2024 for its approach to leveraging artificial intelligence in expediting target detection to accelerate product development:
- AI Algorithms to Predict T Cell Receptor Engagement to Specific HLA+ Peptide Complexes
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
FAQ
What valuation did Tevogen assign to TVGN 489 in the October 29, 2025 release?
What is the projected 5-year revenue cited for Tevogen's HBV-related product (TVGN)?
What progress did Tevogen.AI report on October 29, 2025 for PredicTcell?
Does Tevogen report clinical data for TVGN 489 in the October 29, 2025 announcement?
What intellectual property milestones did Tevogen highlight on October 29, 2025?
How is Tevogen engaging with Long COVID patients according to the October 29, 2025 release?
